ARMED-T Trademark

Trademark Overview


On Thursday, May 9, 2024, a trademark application was filed for ARMED-T with the United States Patent and Trademark Office. The USPTO has given the ARMED-T trademark a serial number of 98542447. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, January 8, 2025. This trademark is owned by CytoArm Co., Ltd.. The ARMED-T trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical services in the field of genetic disorders, cancers, rare diseases, and cardiovascular and immunological diseases and disorders; Health care services, namely, treatment of patients with genetic disorders, cancers, rare diseases, and cardiovascular and immunological diseases and disorders; Medical analysis services for diagnostic and treatment purposes involving a variety of pathological and biochemical examinations provided by medical laboratories; Preparation of prescriptions by pharmacists; Providing pharmacy information, consultancy and advisory services in the nature of information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing medical information, consultancy and advisory services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Regenerative medicine services; Medical treatment using cultured cells; Cultured cell bank services for medical transplantation; Genetic testing for di...
armed-t

General Information


Serial Number98542447
Word MarkARMED-T
Filing DateThursday, May 9, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, January 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkARMED T
Goods and ServicesMedical services in the field of genetic disorders, cancers, rare diseases, and cardiovascular and immunological diseases and disorders; Health care services, namely, treatment of patients with genetic disorders, cancers, rare diseases, and cardiovascular and immunological diseases and disorders; Medical analysis services for diagnostic and treatment purposes involving a variety of pathological and biochemical examinations provided by medical laboratories; Preparation of prescriptions by pharmacists; Providing pharmacy information, consultancy and advisory services in the nature of information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing medical information, consultancy and advisory services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Regenerative medicine services; Medical treatment using cultured cells; Cultured cell bank services for medical transplantation; Genetic testing for diagnostic or treatment purposes; Medical examination; Human tissue bank services

Classification Information


International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, May 9, 2024
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCytoArm Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressTaipei 115
TW

Trademark Events


Event DateEvent Description
Thursday, May 9, 2024NEW APPLICATION ENTERED
Thursday, November 7, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 22, 2024ASSIGNED TO EXAMINER
Wednesday, November 27, 2024NON-FINAL ACTION WRITTEN
Wednesday, November 27, 2024NON-FINAL ACTION E-MAILED
Wednesday, November 27, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 8, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 8, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 8, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED